Tim Smith

This interview segment with Dr. Harris-Tryon further explored some of the key points made in her upcoming talk regarding the microbiology of hidradenitis suppurativa.

During this interview, Dr. Harris-Tryon spoke about the most important points covered in her upcoming talk at the 8th Annual Symposium on Hidradenitis Suppurativa Advances.

This new data indicated that BHRA positivity could potentially be implemented as an omalizumab response predictor and showed the potential for off-label use.

This news was announced following new findings by the FDA due to a recent inspection, though no concerns were listed regarding clinical data, labeling, or safety.

This study indicated the potential of PDLs as a strategy for those that have HDHP-HSAs to address both patient access and affordability of asthma care.

This new data resulted from the first study that found EIS could detect skin barrier dysfunction among children found to have developed atopic dermatitis early on in life.

This new research into detergent’s impact on human skin barrier dysfunction may lead to investigation by public health authorities in the near future due to its implications.

This new position statement by the Congress of the European Academy of Dermatology and Venereology identified several benefits to the implementation of technological innovations in dermatologic care.

This set of measures may promote a more accurate assessment of HS in patients as well as on their life outcomes, with the goal being shared decision-making in clinical practice.

This action represents the first occurrence of the FDA pursuing civil money penalties for the maximum amount against e-cigarette retailers for such an offense.

This study also found a particularly high rate of such obstacles for SGM patients who also identify as being either non-Hispanic Black or Hispanic/Latino.

This new data should be taken into account before biologics prescriptions are made for patients with conditions such as psoriasis.

This segment of Lungcast guest Dr. Barbara Taylor’s discussion covered the topic of new RSV vaccines as well as the spacing of others such as those of COVID-19 and influenza.

In this interview, Dr. Kim described his response to the FDA’s decision not to approve the intranasal epinephrine spray treatment for anaphylaxis and other severe allergic reactions.

The agency’s guideline updates were announced, with the overall goal being to help food facilities in their adherence to current good manufacturing practices.

In this segment of Lungcast’s September episode, guest Dr. Barbara Taylor talked about the potential for a future universal flu vaccine as well as other potential advancements in the field.

In Lungcast’s September episode, guest Dr. Barbara Taylor discusses transmission and diagnosis of RSV as well as the possibility of a so-called ‘triple-demic.’

The new educational initiative was launched to provide useful insights from dermatologists as well as personal accounts by patients with seborrheic dermatitis with many different backgrounds.

New research on the effects of the Canadian wildfires on asthma syndrome in patients sheds light on the downstream effects of ecological disaster on regions outside of those affected.

This new qualitative data may be helpful both for patient-centric decision-making for clinicians as well as endpoints in future research on prurigo nodularis.

This new data indicates that there may be potential for clinicians to maintain their typical lung cancer screening model’s accuracy and also reduce racial and ethnic disparities.

This new research concluded that the unclear nature of safety outcomes indicated additional research and enhanced monitoring of patients’ adverse events may be necessary.

The FDA's announcement requesting further study represents a step back in the process of 'neffy' becoming the first needle-free nasal spray epinephrine alternative.

This segment of Dr. Kim’s interview featured a discussion on the potential advantages and disadvantages of the new ARS-1 epinephrine nasal spray being considered by the FDA.

In a new interview with the HCPLive editorial team, Edwin H. Kim, MD, spoke about the new ARS-1 (Neffy) intranasal epinephrine spray for patients having Type 1 allergic reactions as well as the FDA's upcoming decision on the treatment.

These new results from the pivotal INTEGUMENT-PED trial met both of the investigators' primary and secondary endpoints.

In this interview segment, Jayme Heim, MRS, explored promising treatments on the horizon, hidradenitis suppurativa, and future research on teledermatology and artificial intelligence.

This interview with Jayme Heim featured a discussion about some of the latest treatment-related news for atopic dermatitis and psoriasis.

This new data expands upon limited current research on environmental elements that contribute to the extensive variation in symptoms and infection frequency seen in children.

This new Morbidity and Mortality Weekly Report on the CDC site indicates the importance of influenza vaccination, especially for at-risk populations.